Press Releases Cue Biopharma, Inc.

Equities

CUE

US22978P1066

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
1.63 ^USD	+2.52%		+0.31%	-38.26%

May. 09	Cue Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 08	Transcript : Cue Biopharma, Inc., Q4 2023 Earnings Call, Apr 08, 2024

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights	May. 09	GL
Cue Biopharma to Present at the 20th Annual PEGS Boston Summit	May. 08	GL
Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference	May. 07	GL
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	Apr. 24	GL
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights	Apr. 08	GL
Cue Biopharma to Host Business Update Call and Webcast	Apr. 02	GL
Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium	Feb. 29	GL
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	Feb. 06	GL
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	Feb. 06	AQ
HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	Nov. 23	AQ
Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit	Nov. 22	GL
Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights	Nov. 09	GL
Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November	Nov. 07	GL
Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November	Nov. 07	AQ
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023	Nov. 03	GL
Cue Biopharma to Host Business Update Call and Webcast	Nov. 02	GL
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting	23-09-27	GL
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting	23-09-27	AQ
Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®	23-09-26	GL
Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®	23-09-26	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Cue Biopharma, Inc.

Equities

CUE

US22978P1066

Press Releases

Filters